ArticleCell cycle (Georgetown, Tex.)2020
Novel long noncoding RNA LINC01385 promotes nasopharyngeal carcinoma proliferation via the miR-140-3p/Twist1 signaling pathway.
Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- LncRNA PSMA-AS1 affects glioma cell metastasis through mediating pyroptosis via miR-140-3p/SRSF10 axis.Cytotechnology · 2025Article
- Integrated analysis of the lncRNA-miRNA-mRNA ceRNA network in nasopharyngeal carcinoma.Translational cancer research · 2024Article
- Identification of a seven-lncRNAs panel that serves as a prognosis predictor and contributes to the malignant progression of laryngeal squamous cell carcinoma.Frontiers in oncology · 2023Article
- Long Noncoding RNA CRNDE Functions as an Oncogene to Facilitate Aggressive Behaviors of Nasopharyngeal Carcinoma Cells by Modulating miR-3163/TWIST1 Axis.Molecular biotechnology · 2022Article
- Article
- Long non-coding RNA LUADT1 promotes nasopharyngeal carcinoma cell proliferation and invasion by downregulating miR-1207-5p.Bioengineered · 2021Article
- Knockdown of LINC01385 inhibits osteoarthritis progression by modulating the microRNA-140-3p/TLR4 axis.Experimental and therapeutic medicine · 2021Article
- LncRNA FOXP4-AS1 serves as a biomarker for nasopharyngeal carcinoma diagnosis and prognosis.3 Biotech · 2021Article
- Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma.Diagnostics (Basel, Switzerland) · 2020Review
- Comprehensive analysis of key genes associated with ceRNA networks in nasopharyngeal carcinoma based on bioinformatics analysis.Cancer cell international · 2020Article
- Knockdown of circRNA circ_0087378 Represses the Tumorigenesis and Progression of Esophageal Squamous Cell Carcinoma Through Modulating the miR-140-3p/E2F3 Axis.Frontiers in oncology · 2020Article
Corrections and comments
- Expression of concern · 2022-11-08Author Unresponsive · Notice - Limited or No Information ·
- Expression of concern
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) have been verified as a key modulator in tumor progression. However, the functions of lncRNAs in nasopharyngeal carcinoma (NPC) remain unclear. In the present study, we explored lncRNAs expression patterns in NPC tissues by GEO dataset and selected the high expression lncRNA (LINC01385) to further study. Our data showed that LINC01385 expression was significantly increased NPC and correlated with advanced clinical features and poor prognosis. Function assays showed that knockdown of LINC01385 expression reduced the proliferation and invasion abilities of NPC cells in vitro. In mechanism, LINC01385 acted as a molecular sponge of miR-140-3p in NPC cells, Twist1 mRNA was validated as a direct target of miR-140-3p in NPC cells. The effects of the LINC01385 knockdown on malignant characteristics of NPC cells were greatly attenuated by miR-140-3p inhibition or Twist1 overexpression. Thus, we illustrated that LINC01385 aggravated the progression of NPC by sponging miR-140-3p and upregulating Twist1 expression, which implied LINC01385 might serve as a new potential therapeutic target for NPC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.